INT192762

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 10
Disease Relevance 12.63
Pain Relevance 1.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (SAA1)
Anatomy Link Frequency
blood 2
adipose tissue 2
cartilage 1
fat cells 1
SAA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 314 100.00 Very High Very High Very High
cytokine 110 100.00 Very High Very High Very High
rheumatoid arthritis 60 90.72 High High
Inflammatory marker 4 70.80 Quite High
methotrexate 56 66.56 Quite High
agonist 13 50.00 Quite Low
antagonist 1 34.56 Quite Low
anesthesia 15 5.00 Very Low Very Low Very Low
dexamethasone 15 5.00 Very Low Very Low Very Low
Paracetamol 13 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 817 100.00 Very High Very High Very High
INFLAMMATION 330 100.00 Very High Very High Very High
Alzheimer's Dementia 35 99.92 Very High Very High Very High
Cytomegalovirus Infection 7 98.06 Very High Very High Very High
Fever 7 97.52 Very High Very High Very High
Rheumatic Diseases 6 97.16 Very High Very High Very High
Fatigue 2 96.80 Very High Very High Very High
Cardiovascular Disease 142 95.96 Very High Very High Very High
Amyloidosis 6 95.32 Very High Very High Very High
Weight Loss 105 92.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, pre-operative administration of GH did not alter C-reactive protein (CRP), serum amyloid A (SAA) or interleukin-6 (IL-6, an inflammatory cytokine) release (Mealy et al 1998).
Localization (release) of SAA associated with inflammation, alzheimer's dementia and cytokine
1) Confidence 0.78 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663454 Disease Relevance 0.98 Pain Relevance 0.14
Moreover, A-SAA mRNA levels and A-SAA secretion from adipose tissue were significantly correlated with body mass index (

r = 0.47; p = 0.028 and r = 0.80; p = 0.0002, respectively).

Localization (secretion) of SAA in adipose tissue associated with obesity
2) Confidence 0.64 Published 2006 Journal PLoS Medicine Section Abstract Doc Link PMC1472697 Disease Relevance 1.72 Pain Relevance 0.24
A-SAA appears to be produced in fat cells (or adipocytes) and then released into the blood.
Localization (released) of SAA in blood associated with obesity
3) Confidence 0.64 Published 2006 Journal PLoS Medicine Section Abstract Doc Link PMC1472697 Disease Relevance 2.73 Pain Relevance 0.23
Acute-phase serum amyloid A (A-SAA) mRNA levels, and A-SAA adipose secretion and serum levels were measured in obese and nonobese individuals, obese participants who underwent weight-loss, and persons treated with the insulin sensitizer rosiglitazone.
Localization (secretion) of SAA associated with obesity and alzheimer's dementia
4) Confidence 0.64 Published 2006 Journal PLoS Medicine Section Abstract Doc Link PMC1472697 Disease Relevance 1.53 Pain Relevance 0.22
Obese people have higher numbers of fat cells, which could by itself account for the higher blood levels of A-SAA, but the researchers also found that the average fat cell from an obese individual produces and secretes higher levels of A-SAA than fat cells from lean individuals.
Localization (secretes) of SAA in fat cells associated with obesity
5) Confidence 0.56 Published 2006 Journal PLoS Medicine Section Abstract Doc Link PMC1472697 Disease Relevance 2.41 Pain Relevance 0.20
Moreover, A-SAA mRNA levels and A-SAA secretion from adipose tissue were significantly correlated with body mass index (

r = 0.47; p = 0.028 and r = 0.80; p = 0.0002, respectively).

Localization (secretion) of SAA in adipose tissue associated with obesity
6) Confidence 0.56 Published 2006 Journal PLoS Medicine Section Abstract Doc Link PMC1472697 Disease Relevance 1.73 Pain Relevance 0.24
In light of these concerns, particularly as it relates to the unique role of the SAA in providing sulfates for GAG (glycosaminoglycans) synthesis, it seems essential to determine if the needs for sulfur are being met, in particular as it relates to GAG and GSH (glutathione) in cartilage.
Localization (role) of SAA in cartilage
7) Confidence 0.43 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC2198910 Disease Relevance 0 Pain Relevance 0
Both CRP and SAA were completely normalized in all patients in whom tocilizumab was detected in blood at the trough concentration.
Localization (normalized) of SAA in blood
8) Confidence 0.21 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.38 Pain Relevance 0.18
However, as well as yielding normalization of CRP and SAA levels, inhibition of IL-6 by tocilizumab makes IL-6-induced fever and general fatigue less prominent.
Localization (normalization) of SAA associated with fatigue and fever
9) Confidence 0.21 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.80 Pain Relevance 0
Of equal importance, CMV or ALX-transfected cell incubation with 10 ┬ÁM peptide Ac2-26 (4 h) did not yield any expression/release of endogenous AnxA1 (as assessed by Western blotting in cell-free supernatants), Lipoxin A4 or SAA (assessed by ELISA) (data not shown).
Localization (release) of SAA associated with cytomegalovirus infection
10) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2941452 Disease Relevance 0.35 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox